DOCOMO to Exhibit at World’s Largest Mobile Exhibition: MWC Barcelona 2023
20.1.2023 11:00:00 EET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will organize a full-scale booth at MWC Barcelona 2023, the world’s largest mobile-related exhibition, in Barcelona, Spain from February 27 to March 2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230120005094/en/
NTT DOCOMO Booth at MWC Barcelona 2023 (Graphic: Business Wire)
The DOCOMO booth, which will showcase exhibitions and presentations focused on the main themes of 6G, open radio access networks (Open RAN) and extended reality (XR), will also promote international standardization and global business for next-generation communication technologies. Due to the global pandemic, this will be DOCOMO’s the first onsite appearance at MWC Barcelona since 2019.1
In the 6G section, DOCOMO will present the coming 6G world and advanced wireless technologies that the company is currently developing. This will include a demonstration of the Human Augmentation Platform to communicate haptic sensations between people connected to a 6G network to enable, for example, a musical student to mimic the exact finger motions of a teacher.
In the Open RAN section, DOCOMO will present experiential content to help visitors understand the concept and structure of Open RAN, as well as progress being achieved to enable multi-vendor telecommunication equipment2 to be combined in Open RAN, as well as related collaborations with international carriers.
In the XR section, visitors will experience the metaverse filled with music, anime and movies and also a virtual-live system, both provided by NTT QONOQ, INC., a company launched by DOCOMO’s parent NTT group last October to promote XR business.
Through this exhibition, DOCOMO looks forward to globally communicating its advanced technologies and businesses under the company’s brand slogan “changing worlds with you.”
For more about DOCOMO’s exhibits and the overall exhibition, please refer to the appendix.
1 DOCOMO organized an exhibition in Japan in 2021 and then one online in 2022.
2 Creation of 5G Open RAN Ecosystem to Accelerate Adoption of Open RAN by Operators Globally”
https://www.docomo.ne.jp/english/info/media_center/pr/2021/0208_00.html
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 85 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
Appendix
Overview of NTT DOCOMO Booth at MWC Barcelona 2023
1. Exhibitions
|
Theme |
Exhibits |
Contents |
|
6G |
Human Augmentation Platform |
As an example of this 6G application, presenters will use haptic information to teach musical techniques and guide a robot in whisking green tea. |
|
Wireless Technologies |
DOCOMO’s technical approaches to the realization of 6G will be introduced with detailed explanations. |
|
|
Open RAN |
Interactive Contents |
Experiential content in the form of a simulation game will allow visitors to grasp the overview and structure of Open RAN. |
|
Shared Open Lab
|
This Open RAN verification facility located at the DOCOMO R&D Center in Japan will be introduced in 3D. |
|
|
XR |
XR World |
This metaverse diorama will enable people to view a life-size Godzilla from various angles. |
|
Matrix Stream |
Presenting NTT QONOQ’s virtual-live and general-purpose video-delivery system for extended reality |
|
|
Mixed Reality Animals—Volumetric Video × Magic Leap 2 |
Videos of real cats and penguins will be converted to 3DCG and projected into real space using a Magic Leap 2 MR headset. |
2. NTT DOCOMO Booth Location
4E50, Hall 4
3. Presentations
|
1 |
Broadcast Stage
|
|
2 |
5G Futures Summit
|
Note: The content and schedule of the presentations are subject to change. Please check the official website of MWC Barcelona 2023 for the latest information.
Reference
MWC Barcelona 2023
1. Dates & Times
Monday, February 27 to Thursday, March 2
08:30 to 19:00, except last day from 08:30 to 16:00 (all times local)
2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
3. Official Website
https://www.mwcbarcelona.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230120005094/en/
Contact information
For further information, please contact:
NTT DOCOMO
Mr. Ryoichi Sakurai or Mr. Yasutaka Imai
Brand Communication Department
Tel: +81 (0)3 5156 1366
Fax: +81 (0)3 5501 3408
Mail: global_pr@nttdocomo.com
www.docomo.ne.jp/english/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom